2025年1月13日,先声药业集团(2096.HK)旗下抗肿瘤创新药公司先声再明与全球生物制药公司艾伯维(AbbVie)宣布,双方已就先声再明的在研候选药物SIM0500达成许可选择协议。SIM0500目前正在中美两国开展针对复发或难治性多发性骨髓瘤(MM)的临床I期研究。根据该协议条款,先声再明将从艾伯维收取首付款,以及最高10.55亿美金的选择性权益付款和里程碑付款。多发性骨髓瘤是第二大血液瘤...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.